Physician profile
Allison E Kerr
NPI 1851317473
$8,645.92
in general payments reported to CMS, 2019-2025
32 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $957 · 2021: $1,121 · 2022: $1,577 · 2023: $1,229 · 2024: $1,353 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,208.97 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $1,064.16 | 2019-2025 | Korlym |
| Lilly USA, LLC | $982.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $703.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $474.29 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $467.84 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $445.47 | 2019-2024 | Farxiga |
| Insulet Corporation | $328.15 | 2019-2024 | Omnipod |
| Cequr Corporation | $277.10 | 2023-2025 | Cequr Simplicity |
| Mannkind Corporation | $241.81 | 2022-2024 | Afrezza |
| Abbott Laboratories | $236.45 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $225.43 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.52 | 2019-2024 | Tradjenta, Jardiance |
| Janssen Pharmaceuticals, INC | $189.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $180.29 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $178.80 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $178.78 | 2021-2025 | Minimed 780g |
| Abbvie INC. | $167.31 | 2020-2022 | |
| Medtronic Minimed, INC. | $161.95 | 2019-2020 | |
| Madrigal Pharmaceuticals | $121.34 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $117.76 | 2023-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $102.60 | 2024-2025 | Tepezza |
| Alexion Pharmaceuticals, INC. | $85.40 | 2024-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $81.55 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $65.01 | 2019-2021 | |
| Sequel Med Tech, LLC | $56.12 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $21.54 | 2023 | |
| Pfizer INC. | $18.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.27 | 2025 | |
| Zealand Pharma US, INC. | $14.42 | 2022 | |
| Beta Bionics, INC. | $14.13 | 2023 | Ilet Bionic Pancreas |
| Arbor Pharmaceuticals, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Kerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.